[ad_1]
![Baxter International logo "title =" Baxter International logo "class =" companylogo "/> Achmea Investment Management BV reduced its stake in Baxter International Inc. (NYSE: BAX) shares by 14.7% in the second quarter, according to its institutional investor held 172,563 shares of the medical device provider after selling 29,734 shares during the period, while the assets of Achmea Investment Management BV in Baxter International s & 39; amounted to $ 12,740,000 at the end of last quarter 19659002] A number of other institutional investors and hedge funds also recently bought and sold shares, Old Mutual Global Investors UK Ltd. increased its stake in Baxter International's 13.0% First Quarter Holds 3,502,519 Medical Device Vendor Shares valued at $ 227,803,000 after acquiring 404,135 additional shares in the last quarter quarter, es Group Inc. increased its interest in Baxter International by 103.8% in the first quarter. PNC Financial Services Group Inc. now holds 1,652,618 shares of a medical device provider valued at $ 107,487,000 after acquiring an additional 841,733 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its interest in Baxter International by 0.3% in the first quarter. Sumitomo Mitsui Trust Holdings Inc. now holds 1,589,488 shares of a medical device provider valued at $ 103,380,000 after acquiring 4,379 additional shares in the last quarter. The California Public Employees Retirement System increased its stake in Baxter International by 3.1% in the first quarter. The California Public Employees Retirement System now owns 1,516,440 shares of the medical device provider valued at $ 98,629,000 after acquiring an additional 45,295 shares in the last quarter. Finally, Calamos Advisors LLC increased its stake in Baxter International by 1.6% in the second quarter. Calamos Advisors LLC now holds 1,346,341 shares of the medical device provider valued at $ 99,414,000 after acquiring 20,858 additional shares in the last quarter. 83.35% of the shares are held by institutional investors. </p>
<p> BAX has been the subject of several reports by research analysts. Zacks Investment Research has taken Baxter International's shares from a "hold" rating to a "buy" rating and set a target price of $ 74.00 for the company in a research note on Wednesday, April 11th. ValuEngine updated its shares of Baxter International, which went from a "hold" note to a "buy" note in a research report on Monday, April 2nd. Piper Jaffray Companies reiterated an "overweight" rating and set a price target of $ 77.00 on Baxter International shares in a research report on Thursday, May 31. Bank of America increased its price target on Baxter International's shares from $ 73.00 to $ 83.00 and gave the company a "buy" rating in a research report on Tuesday, May 22nd. Finally, Citigroup increased its target price on Baxter International shares from $ 70.00 to $ 72.00 and granted the company a "neutral" rating in a research report on Monday, April 30th. Seven equity research analysts have assigned a passing grade to the stock, ten have assigned a note to the purchase and one has issued a solid buy note to the company. The stock has a "Buy" rating by consensus and an average price target of $ 73.73. </p>
<p> Baxter International opened Friday at $ 73.71, according to reports from MarketBeat Ratings. Baxter International Inc. has a 52-week low of $ 58.81 and a high of $ 52.51 in 52 weeks. The company has a debt ratio of 0.39, a ratio of 2.63 and a ratio of 2.03. The company has a market capitalization of $ 40.97 billion, a price / earnings ratio of 29.72, a price / earnings ratio of 1.98 and a beta of 0.81. </p>
<p> Baxter International (NYSE: BAX) released its financial results for the last time on Thursday, July 26. The medical device provider reported earnings per share (EPS) of $ 0.77 for the quarter, exceeding $ 0.76 by Thomson Reuters consensus estimate of $ 0.71. The company achieved a turnover of 2.84 billion dollars during the quarter, against 2.83 billion dollars for analysts. Baxter International recorded a net margin of 7.75% and a return on equity of 15.70%. The company 's revenues increased 9.1% from one year to the next. In the same quarter last year, the company earned $ 0.63 per share. Research analysts expect Baxter International Inc. to post EPS 2.89 for the current fiscal year. </p>
<p> The company also recently announced a quarterly dividend, which will be paid on Monday, October 1st. Shareholders of record on Friday, August 31 will receive a dividend of $ 0.19. The ex-dividend date of this dividend is Thursday, August 30th. This represents an annualized dividend of $ 0.76 and a dividend yield of 1.03%. The dividend payout ratio (DPR) of Baxter International is currently 30.65%. </p>
<p> In addition, UDC Brik V. Eyre sold 20,000 shares of the fund in a transaction dated Tuesday, May 15. The shares were sold at an average price of $ 70.57, for a total value of $ 1,411,400.00. As a result of the sale, the Senior Vice-President now holds 85,115 shares of the Company, valued at approximately $ 6,006,565.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available via this hyperlink. In addition, the UDC Scott Pleau sold 10,686 shares of the company in a transaction dated Tuesday, July 10. The stock was sold at an average price of $ 75.00, for a total transaction of $ 801,450.00. As a result of the sale, the Senior Vice President now holds 26,349 shares of the Company, valued at approximately $ 1,976,175. The disclosure for this sale can be found here. Insiders sold a total of 89,477 shares valued at $ 6,486,117 over the last 90 days. Insiders of the company own 0.05% of the shares of the company. </p>
<p> <strong> Company Profile Baxter International </strong> </p>
<p> Baxter International Inc. provides a portfolio of health products. The company operates across North and South America; Europe, Middle East and Africa; and the Asia-Pacific segments. It offers peritoneal dialysis and hemodialysis, as well as additional dialysis therapies and services; renal replacement therapies and other intensive care unit-based organ therapy therapies; sterile intravenous (IV) solutions, intravenous therapies, infusion pumps, dosing sets and drug reconstitution devices; </p>
<p> To learn more about diversification <!--ViewCount:ArticleHistoryID=21940766&PostDate=2018-7-27&type=f&id=3771675--> </p>
<p> <strong> Want to know which other hedge funds hold BAX? </strong> Visit HoldingsChannel.com to get the latest 13F deposits and insider trading for Baxter International Inc. (NYSE: BAX). </p>
<p style=](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&zc=1&src=https://www.marketbeat.com/logos/baxter-international-inc-logo.jpg)
Receive News Updates Baxter International Daily – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings for Baxter International and related companies with the free daily newsletter from MarketBeat.com.
[ad_2]
Source link
